Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1b/2, Open-Label, Randomized Platform Study Evaluating The Efficacy and Safety of AB928 Based Treatment Combinations in Patients With Metastatic Colorectal Cancer

Next Previous
X
Search
Trial Profile

A Phase 1b/2, Open-Label, Randomized Platform Study Evaluating The Efficacy and Safety of AB928 Based Treatment Combinations in Patients With Metastatic Colorectal Cancer

Status: Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 25 Sep 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Etrumadenant (Primary) ; Quemliclustat (Primary) ; Zimberelimab (Primary) ; Bevacizumab; Fluorouracil; Folinic acid; Oxaliplatin; Regorafenib
  • Indications Adenocarcinoma; Colorectal cancer
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms ARC-9
  • Sponsors Arcus Biosciences

    • Most Recent Events

    • 02 Aug 2024 Planned End Date changed from 1 Jul 2024 to 1 Oct 2024.
    • 02 Aug 2024 Planned primary completion date changed from 1 Jul 2024 to 1 Oct 2024.
    • 04 Jun 2024 Results (from Cohort B, n=112) assessing safety and efficacy of etrumadenant based treatment combinations in previously treated metastatic colorectal cancer presented at the 60th Annual Meeting of the American Society of Clinical Oncology

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top